Avanos Medical, Inc. has recently announced its acquisition of Nexus Medical, LLC, a company known for its tko® anti-reflux needleless connector technology. The tko® connector is designed to support safer nutrition and medication delivery in critical care settings, particularly in neonatal and pediatric intensive care units (NICUs and PICUs). This acquisition is in line with Avanos' strategy to provide smarter, safer solutions across the critical care spectrum.
The tko® needleless connector features a patented, pressure-activated tri-seal silicone valve that minimizes blood reflux, which is a known contributor to catheter occlusions, therapy delays, and infection risk during IV-based nutrition and medication delivery. Avanos' chief commercial officer, Kerr Holbrook, highlighted that the tko® technology is expected to deliver immediate value in NICU and PICU care, offering clinicians a practical and trusted solution to reduce disruptions and deliver therapy with greater consistency and ease.
The acquisition was financed with available cash, and Avanos expects it to be immediately accretive to both revenue growth and earnings per share. This move reinforces the company's focus on safe, reliable therapy delivery for the neonatal patient population and aligns with its commitment to addressing crucial healthcare needs.
As a leading medical technology company, Avanos is dedicated to delivering clinically superior medical device solutions that help patients in their recovery journey. The company holds leading market positions in multiple product categories and is committed to providing a vital lifeline for nutrition to patients from hospital to home, as well as reducing the use of opioids while facilitating patients' transition from surgery to recovery. Following these announcements, the company's shares moved 1.35%, and are now trading at a price of $12.385. Check out the company's full 8-K submission here.
